Form 4: Tyra Biosciences Director Sells Shares Under Pre-Arranged Trading Plan

Tyra Biosciences, Inc. Director Gilla Kaplan sold a total of 9,578 shares of common stock in mid-June 2025, as disclosed in a recent SEC Form 4 filing, with transactions executed under a Rule 10b5-1 trading plan.

Summary

• Gilla Kaplan, a Director of Tyra Biosciences, Inc. (TYRA), reported the sale of common stock.
• On June 17, 2025, 10 shares were sold at a price of $10.35 per share.
• On June 18, 2025, an additional 9,568 shares were sold at a weighted average price of $9.7822 per share, with prices ranging from $9.55 to $9.93.
• These transactions were conducted pursuant to a Rule 10b5-1(c) trading plan, indicating pre-scheduled sales.
• Following these sales, Gilla Kaplan beneficially owns 28,231 shares of Tyra Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the disclosure that the transactions were made pursuant to a Rule 10b5-1 plan significantly mitigates concerns about opportunistic selling, indicating a pre-planned divestment rather than a reaction to new, adverse information.

Positives

• The sales were conducted under a Rule 10b5-1(c) trading plan, which indicates pre-scheduled transactions rather than opportunistic selling based on new, non-public information, mitigating potential negative interpretations.

Negatives

• A director selling shares reduces their direct ownership stake in the company, which some investors may view as a slight negative signal.

Future Outlook

NA

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a slight negative signal, though this is largely mitigated by the disclosure of a 10b5-1 plan, potentially leading to minor short-term price fluctuations or no significant impact.

Key Dates

Recommendation

Keywords

Tyra Biosciences, TYRA, SEC Form 4, Insider Trading, Stock Sale, Director, Gilla Kaplan, 10b5-1 Plan, Equity Transaction, Beneficial Ownership